Piper Sandler analyst Jason Bednar raised the firm’s price target on Merit Medical to $92 from $85 and keeps an Overweight rating on the shares. The firm says Merit Medical has been a model of consistency from a reporting standpoint, and that it has no reason to believe Q2 will be any different. While the stock is among the more crowded longs, Piper likes the potential for management to raise guidance for the second straight quarter, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MMSI:
- Merit Medical Systems to Announce Second Quarter 2023 Results On July 25, 2023
- Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.
- Merit Medical Announces New Five-Year Senior Secured Credit Agreement
Questions or Comments about the article? Write to editor@tipranks.com